Kristan Hawkins, head of Students for Life of America, was equally jubilant, posting, “WIN: Costco said NO to distributing deadly Chemical Abortion Pills.” She added, “Great to see 500+ pharmacies truly living up to their slogan: ‘Simplifying Home and LIFE.’ Protecting moms, protecting babies. This is what winning looks like.”
The ripple effects are already being felt with pro-life advocates turning up the pressure on other retailers and even the FDA, demanding stronger safeguards for unborn lives and women’s health.
Abortion is one of the most critical issues of our time, with the use of abortion pills being the primary driver of the issue as more than 60% of all abortions in the US being procured through the abortion pill.
Lila Rose of Live Action didn’t mince words, urging other chains to “follow Costco’s lead and immediately stop trafficking in the deaths of children” while calling on the FDA to yank mifepristone’s approval entirely.
The fight over mifepristone isn’t just about access—it’s about safety. Paired with misoprostol, the drug is used in chemical abortions to terminate a pregnancy and expel the developing child. But things can go wrong, and for every one women taking the drug out of every ten, it does.
Incomplete abortions often lead to serious complications like infections or severe bleeding, and countless women have reported intense pain and trauma which is commonly brushed off as “mild” by abortion providers.
Pro-lifers also highlight darker concerns, pointing to cases where abortion pills have been weaponized. A chilling example surfaced in Texas, where a woman sued a Marine who allegedly slipped her 10 abortion pills, killing her unborn daughter against her will. Stories like these have fueled demands for tighter regulations and greater scrutiny of the drug’s distribution.
FDA Commissioner Marty Makary has promised to take a hard look at mifepristone’s safety, writing in a letter to Senator Josh Hawley: “As the Commissioner of Food and Drugs, I am committed to conducting a review of mifepristone and working with the professional career scientists at the Agency who review this data.”
He added, “As with all drugs, FDA continues to closely monitor the postmarketing safety data on mifepristone for the medical termination of early pregnancy.” For now, that review is a glimmer of hope for those pushing for change.